Quince Therapeutics said its pivotal Phase III Neat trial of dexamethasone sodium phosphate encapsulated in autologous erythrocytes (eDSP) failed to meet its primary endpoint in ataxia‑telangiectasia (A‑T). The company halted the program and announced it would stop development of the therapy. The announcement triggered a steep share-price collapse and investor reassessment of the firm’s valuation. Top-line data showed no statistically significant improvement on the modified ataxia rating scale at six months; secondary endpoints also missed. Management said it would cease further investment in the asset, leaving the company to re-evaluate strategy and capital needs.